Assessing evidence from clinical trials in chronic hepatitis C

被引:2
作者
Bacon, BR [1 ]
机构
[1] St Louis Univ, Sch Med, Ctr Liver, Div Gastroenterol & Hepatol, St Louis, MO 63110 USA
关键词
hepatitis C; interferon; investigational drugs; ribavirin; viramidine;
D O I
10.1111/j.1365-2893.2006.00755.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C is a global problem with significantly associated morbidity and mortality. Although some recent therapeutic advances have shown rates of sustained virologic remission of 50% or higher, combination therapy with interferon and ribavirin is often not well tolerated and is giving rise to a growing number of nonresponders. As a result, a large number of experimental drugs for the treatment of chronic hepatitis C are in development. As the clinical trial reports are made available, physicians need to become familiar with issues related to the design of these studies and to develop strategies to interpret the evidence they yield. The articles in this supplement describe the issues in clinical trial design and the evaluation of evidence from clinical trials in patients with chronic hepatitis C.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 40 条
[1]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[2]  
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[3]  
Biggins Scott W, 2005, Clin Liver Dis, V9, P505, DOI 10.1016/j.cld.2005.05.004
[4]   Viral hepatitis and other infectious diseases in a homeless population [J].
Cheung, RC ;
Hanson, AK ;
Maganti, K ;
Keeffe, EB ;
Matsui, SM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 34 (04) :476-480
[5]   Natural history of hepatitis C: Its impact on clinical management [J].
Di Bisceglie, AM .
HEPATOLOGY, 2000, 31 (04) :1014-1018
[6]  
Dias N, 2002, MOL CANCER THER, V1, P347
[7]   HEPATITIS-C VIRUS GENOTYPES - AN INVESTIGATION OF TYPE-SPECIFIC DIFFERENCES IN GEOGRAPHIC ORIGIN AND DISEASE [J].
DUSHEIKO, G ;
SCHMILOVITZWEISS, H ;
BROWN, D ;
MCOMISH, F ;
YAP, PL ;
SHERLOCK, S ;
MCINTYRE, N ;
SIMMONDS, P .
HEPATOLOGY, 1994, 19 (01) :13-18
[8]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[9]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244
[10]   Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients [J].
Gish, R ;
Arora, S ;
Nelson, D ;
Fernandez, H ;
Lamon, K .
JOURNAL OF HEPATOLOGY, 2004, 40 :141-142